JP2018511319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018511319A5 JP2018511319A5 JP2017550494A JP2017550494A JP2018511319A5 JP 2018511319 A5 JP2018511319 A5 JP 2018511319A5 JP 2017550494 A JP2017550494 A JP 2017550494A JP 2017550494 A JP2017550494 A JP 2017550494A JP 2018511319 A5 JP2018511319 A5 JP 2018511319A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hla
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims description 51
- 108010024164 HLA-G Antigens Proteins 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 44
- 108091033319 polynucleotide Proteins 0.000 claims description 41
- 102000040430 polynucleotide Human genes 0.000 claims description 41
- 239000002157 polynucleotide Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 40
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 39
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 230000000295 complement effect Effects 0.000 claims description 29
- 239000000523 sample Substances 0.000 claims description 28
- 150000007523 nucleic acids Chemical group 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 238000009396 hybridization Methods 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 238000011534 incubation Methods 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 238000003364 immunohistochemistry Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 238000000684 flow cytometry Methods 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 208000013076 thyroid tumor Diseases 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 108091035707 Consensus sequence Proteins 0.000 claims description 2
- 241000282324 Felis Species 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 238000000338 in vitro Methods 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139617P | 2015-03-27 | 2015-03-27 | |
| US62/139,617 | 2015-03-27 | ||
| PCT/US2016/024361 WO2016160622A2 (en) | 2015-03-27 | 2016-03-25 | Hla-g as a novel target for car t-cell immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018511319A JP2018511319A (ja) | 2018-04-26 |
| JP2018511319A5 true JP2018511319A5 (cg-RX-API-DMAC7.html) | 2019-05-09 |
| JP6843062B2 JP6843062B2 (ja) | 2021-03-17 |
Family
ID=57006294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550494A Expired - Fee Related JP6843062B2 (ja) | 2015-03-27 | 2016-03-25 | Ｃａｒ ｔ細胞免疫療法のための新規標的としてのｈｌａ−ｇ |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20190119385A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3274715A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6843062B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107533051B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016243128A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2981166A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL254699A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016160622A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018074847A2 (pt) | 2016-06-03 | 2019-03-26 | Invectys | anticorpos específicos anti hla-g |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| CN106632661A (zh) * | 2017-01-10 | 2017-05-10 | 天津东亚生物技术有限公司 | 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用 |
| JP7618192B2 (ja) | 2017-03-28 | 2025-01-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 移植された組織を拒絶反応から保護するための方法 |
| CN110869494B (zh) * | 2017-06-12 | 2025-02-18 | 西奈卫生系统公司 | 无需全身性免疫遏制的同种异体移植物耐受 |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| AR115052A1 (es) * | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| CN109111525B (zh) * | 2018-05-24 | 2021-10-29 | 卢英 | 一种hla-g嵌合抗原受体、编码序列和表达载体以及应用 |
| EA202190181A1 (ru) * | 2018-07-04 | 2021-05-27 | Сайтоиммьюн Терапьютикс, Инк. | Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1 |
| AU2019328677A1 (en) | 2018-08-31 | 2021-04-01 | Invectys SA | Chimeric antigen receptors against multiple HLA-G isoforms |
| CA3110946A1 (en) * | 2018-08-31 | 2020-03-05 | Invectys SA | Method to assess car functionality |
| CN110903399B (zh) * | 2018-09-17 | 2022-02-01 | 台湾中国医药大学附设医院 | 嵌合抗原受体、其核酸、表达质体、细胞、用途及组合物 |
| TWI694083B (zh) * | 2018-09-17 | 2020-05-21 | 中國醫藥大學附設醫院 | 嵌合抗原受體、核酸、嵌合抗原受體表達質體、表達嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| SG11202103104RA (en) | 2018-09-27 | 2021-04-29 | Tizona Therapeutics | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies |
| JP2022520106A (ja) | 2019-02-15 | 2022-03-28 | ユニバーシティ オブ サザン カリフォルニア | Ｌｙｍ－１およびｌｙｍ－２抗体組成物ならびに改善されたｃａｒ構築物 |
| TWI717880B (zh) * | 2019-10-24 | 2021-02-01 | 中國醫藥大學附設醫院 | Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物 |
| CN110904024A (zh) * | 2019-11-13 | 2020-03-24 | 武汉济源高科技有限公司 | 一种悬浮细胞培养中去除死细胞的方法 |
| IL293716A (en) | 2019-12-11 | 2022-08-01 | A2 Biotherapeutics Inc | Lilrb1-based chimeric antigen receptor |
| CN113528448B (zh) * | 2020-04-14 | 2023-01-24 | 同济大学 | 一种人胚胎干细胞的构建方法 |
| AU2021329375A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| IL300629A (en) | 2020-08-20 | 2023-04-01 | A2 Biotherapeutics Inc | Preparations and methods for the treatment of EGFR positive cancer |
| AU2021329371A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| JP7326584B2 (ja) | 2020-12-17 | 2023-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｈｌａ－ｇ抗体及びその使用 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CN118234744A (zh) * | 2021-05-26 | 2024-06-21 | 得克萨斯大学体系董事会 | 靶向hla-g阳性癌症的嵌合抗原受体 |
| CN115925930B (zh) * | 2021-11-04 | 2025-10-31 | 台州恩泽医疗中心(集团) | 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途 |
| KR20230141534A (ko) * | 2022-03-25 | 2023-10-10 | 에이치케이이노엔 주식회사 | 항-hla-g 키메라 항원 수용체 및 이의 용도 |
| CN119768507A (zh) * | 2022-06-24 | 2025-04-04 | 怡诺安有限公司 | 表达免疫检查点调节剂的免疫细胞及其用途 |
| WO2024118469A1 (en) * | 2022-11-28 | 2024-06-06 | Invectys, Inc. | Humanized anti-hla-g chimeric antigen receptors and uses thereof |
| CN116699130B (zh) * | 2023-04-17 | 2025-09-16 | 中国农业科学院都市农业研究所 | 一种快速检测猪传染性胃肠炎冠状病毒的乳胶免疫层析试纸条及其制备方法 |
| CN119569893B (zh) * | 2023-09-06 | 2025-10-31 | 上海恩凯细胞技术有限公司 | 特异性靶向肿瘤的嵌合抗原受体细胞及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996031604A1 (en) * | 1995-04-07 | 1996-10-10 | The Regents Of The University Of California | Antibodies for the detection of hla-g |
| AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
| AU780825B2 (en) * | 1999-09-27 | 2005-04-21 | Clifford L. Librach | Detection of HLA-G |
| US7429382B2 (en) * | 2002-10-16 | 2008-09-30 | Corixa Corporation | Antibodies that bind cell-associated CA 125/O772P and methods of use thereof |
| CA2518552A1 (en) * | 2003-03-11 | 2004-09-23 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related disease |
| CN1312182C (zh) * | 2004-10-26 | 2007-04-25 | 四川新创生物科技有限公司 | 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用 |
| CN101358964B (zh) * | 2007-07-31 | 2012-06-20 | 叶尚勉 | 含抗hla-g的单克隆抗体的癌症诊断试剂盒及其应用 |
| CN101493462A (zh) * | 2008-01-25 | 2009-07-29 | 广州天美生物技术有限公司 | 化学发光免疫分析检测hla-g超敏感方法 |
| CN101520458B (zh) * | 2008-02-25 | 2014-04-16 | 广州天美生物技术有限公司 | 金标免疫分析检测hla-g及其抗体的简易方法 |
| WO2010146094A1 (en) * | 2009-06-18 | 2010-12-23 | Hla-G Technologies | Hla-g alpha 1 multimers and pharmaceutical uses thereof |
| CA2764649C (en) * | 2009-06-25 | 2019-02-26 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof |
| CN101967191A (zh) * | 2009-07-28 | 2011-02-09 | 广州天美生物技术有限公司 | Hla-g抗体制备方法及其在医学中的应用 |
| FR2967579B1 (fr) * | 2010-11-23 | 2013-11-22 | Ets Francais Du Sang | Utilisation d'une isoforme d'hla-g comme agent anti-resorption osseuse |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012106333A1 (en) * | 2011-01-31 | 2012-08-09 | Esoterix Genetic Laboratories, Llc | Methods for enriching microparticles or nucleic acids using binding molecules |
| SG11201404769UA (en) * | 2012-02-22 | 2014-11-27 | Univ Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| EP2730588A1 (en) * | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| CN103756967B (zh) * | 2013-12-31 | 2018-09-21 | 卢英 | 抗hla-g的单克隆抗体偶联免疫磁珠在肿瘤细胞分选中的应用 |
-
2016
- 2016-03-25 US US15/561,966 patent/US20190119385A1/en not_active Abandoned
- 2016-03-25 WO PCT/US2016/024361 patent/WO2016160622A2/en not_active Ceased
- 2016-03-25 CA CA2981166A patent/CA2981166A1/en not_active Abandoned
- 2016-03-25 JP JP2017550494A patent/JP6843062B2/ja not_active Expired - Fee Related
- 2016-03-25 AU AU2016243128A patent/AU2016243128A1/en not_active Abandoned
- 2016-03-25 CN CN201680024710.5A patent/CN107533051B/zh not_active Expired - Fee Related
- 2016-03-25 EP EP16773875.6A patent/EP3274715A4/en not_active Withdrawn
-
2017
- 2017-09-26 IL IL254699A patent/IL254699A0/en unknown
-
2020
- 2020-04-07 US US16/841,810 patent/US20210070864A1/en not_active Abandoned
-
2024
- 2024-03-28 US US18/620,185 patent/US20240392011A1/en active Pending